Home

Assessment and Tracking of Long-Term Alefacept Safety (ATLAS)

Study Description: 
Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
Skin Disease: 
Psoriasis
Study Start Date: 
July 2003
Estimated completion date: 
December 2013
Study Location(s): 
Winnipeg, Quispamsis, St. John's, Hamilton, Newmarket, London, Markham, Kingston, Peterborough, Sudbury, Toronto, North York, Windsor, Alma, Quebec City, Montreal, Gatineau, Pierrefonds, Laval, Regina
Province: 
Manitoba
New Brunswick
Newfoundland and Labrador
Ontario
Quebec
Saskatchewan
Agegroup: 
18+ years
Gender: 
Both
Healthy Volunteers: 
No
Study Director/Investigator: 
Astellas Pharma US, Inc.
Contact: 
Clinsys 866-285-2755

Contact Information:

Canadian Skin Patient Alliance
2446 Bank Street, Suite 383
Ottawa, Ontario
K1V 1A8
 

Sheri Pilon, Program & Services Manager
phone: 613-224-4266
fax: 613-422- 4267
 

pageTracker._trackPageview();